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MicroRNAs (miRNAs) are small non-coding RNAs that fine-tune the cell response to 
a changing environment by modulating the cell transcriptome. miR-155 is a multi-
functional miRNA enriched in cells of the immune system and is indispensable for the 
immune response. However, when deregulated, miR-155 contributes to the develop-
ment of chronic inflammation, autoimmunity, cancer, and fibrosis. Herein, we review 
the evidence for the pathogenic role of miR-155 in driving aberrant activation of the 
immune system in rheumatoid arthritis, and its potential as a disease biomarker and 
therapeutic target.
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iNTRODUCTiON
Epigenetic modification represents an important mechanism of regulating gene expression that 
enables cells to respond appropriately to a changing environment. The mechanisms of epigenetic 
modification include, e.g., acetylation of histones, methylation of gene promoters, and silencing of 
mRNA transcripts by microRNAs (miRNA) (1). miRNAs are a family of short, non-coding RNAs, 
acting at the posttranscriptional level (2, 3), that fine-tune mRNA transcription (4). More than 2,000 
miRNAs have been identified in humans, and computational predictions show that these regulate 
the expression of approximately 60% of all human protein-coding genes (5). miRNAs are pleotropic; 
a single miRNA can regulate a cellular response by targeting multiple components of a biological 
pathway (2). More than 100 different miRNAs are expressed by cells of the immune system together 
influencing the pathways that control the development and function of cells of innate and adaptive 
immune responses (2, 6, 7). Identifying disease-specific miRNAs improved the understanding of 
molecular pathways involved in diseases, and provided an evidence-base for new therapeutic strate-
gies, e.g., in cancer (8) and tendinopathy (9).
Rheumatoid arthritis (RA) is an autoimmune disease that affects approximately 1% of the global 
population and leads to progressive loss of joint function (10). Currently, more than half of RA 
patients do not achieve sustained drug-induced disease remission (11), which constitutes an impor-
tant clinical unmet need. A better understanding of the disease process is required to improve the 
treatment options for patients resistant to current therapeutics and to provide an evidence base for 
personalized medicine.
A decade of research has shown that aberrant expression of miRNAs underlies the immune 
response and stromal cell activation in RA (2, 12). miR-155 is a master-regulator of the immune 
response and the aim of the present review is to discuss its role in the immuno-pathogenesis of RA 
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and its potential as a disease activity biomarker and therapeutic 
target.
miRNA BiOGeNeSiS AND MeCHANiSM 
OF ACTiON
MicroRNAs are ~23  nt small non-coding RNAs that regulate 
mRNA expression at the posttranscriptional level by directing 
mRNA degradation or translational repression. They fine-tune 
expression of their target genes (by approximately 1.2-fold to 
fourfold) and correspondingly affect biological pathway func-
tion (2). miRNAs bind complementary seed-region sequences 
in the 3′ untranslated regions (UTRs) of specific target mRNAs 
leading to the repression of protein production. Each miRNA 
has the potential to repress many target mRNAs, often in the 
same molecular pathway, highlighting the sophistication of this 
epigenetic regulation.
MicroRNAs emerge from long primary transcripts (pri-
miRNAs) transcribed from independent miRNA coding genes 
or from introns of protein-coding mRNAs (13, 14). After 
transcription, pri-miRNAs are capped, poly-adenylated, and 
then cleaved into ~70 nt hairpin structures (pre-miRNAs) by a 
nuclear microprocessor complex composed of RNase III-type 
endonuclease Drosha and the DiGeorge critical region 8 protein. 
DGCR8 is essential for Drosha activity and is capable of binding 
single-stranded fragments of the pri-miRNA that are required 
for proper processing. Pre-miRNAs are then exported from the 
nucleus to the cytoplasm through Exportin-5 in a GTP-dependent 
mechanism. In the cytoplasm, pre-miRNAs are then cleaved by 
Dicer; a RNase III-type enzyme that acts with its cofactor TAR 
RNA-binding protein 2 resulting in RNA duplexes of ~22–23 nt 
in length. Subsequently, an argonaute (Ago) protein and a 182-
kDa glycine–tryptophan repeat-containing protein bind to these 
RNA duplexes forming the core of a multi-subunit complex 
called the miRNA-mediated silencing complex (miRISC). Once 
assembled into the miRISC, through base-pairing interactions 
between nucleotides 2 and 8 of the miRNA (the seed region) 
and complementary nucleotides predominantly in the 3′-UTR 
of mRNAs, they act as repressor of mRNA translation (15–18).
The miR-155 gene was initially described as the B-cell integra-
tion cluster gene (bic) in chickens, which induced leucocytosis 
when activated by a viral promoter insertion that increased bic 
transcription (19). Following this finding, a homologous gene to 
bic was identified in humans and mice (20). Human and murine 
bic cDNA have >70% identity (20). Bic is strongly expressed 
in the thymus and spleen, and can be detected in other tissues, 
including liver, lung, and kidney (20–22). At the cellular level, 
analysis of small RNA clone libraries by Landgraf and colleagues 
demonstrated that miR-155 is expressed in hematopoietic 
stem-progenitor cells and mature hematopoietic cells, including 
monocytes, granulocytes, B-cells, and T-cells (23). Subsequent 
experiments showed that miR-155 plays an essential role in 
controlling both myelopoiesis and erythropoiesis from CD34+ 
hematopoietic stem-progenitor cells (24, 25).
The miRNA duplex contains two strands identified with either 
the suffix -5p (from the 5′ arm of pre-miR; i.e., miR-155-5p) or 
-3p (from the 3′ arm of pre-miR; i.e., miR-155-3p) (26). One of the 
strands of the duplex is normally discarded (the passenger strand; 
annotated *) while the retained strand guides eventual mRNA 
target selection (the guide strand). Thermodynamic properties 
of the duplex appear to determine strand selection; the strand 
with the weakest binding at the 5′-end of the duplex is more likely 
to become the guide strand. Other key characteristics of miRNA 
guide strands are a U-bias at the 5′-end and an excess of purines 
(A/G rich), whereas the passenger strands have a C-bias at the 5′-
end and an excess of pyrimidines (U/C rich) (27). However, the 
preferred guide strand can be changed by a single point mutation 
in the duplex (28), posttranscriptional modification of the duplex 
(29), and the type of proteins associated with Ago2 in the RISC 
complex (e.g., trans-activation response RNA-binding protein 
versus protein activator of dsRNA-dependent protein kinase) 
(30). Thus, there is increasing evidence demonstrating that both 
arms of the pre-miRNA hairpin can give rise to guide miRNAs 
(31, 32) that are biologically functional. In general, miR-155-3p 
is considered to be the passenger strand (*), and its expression 
levels are typically 20-fold to 200-fold lower than miR-155-5p. 
However, despite this difference in expression level, miR-155-3p 
(*) can be functional, e.g., following TLR7 ligand stimulation 
of plasmocytoid dendritic cells (pDCs), miR-155-3p is rapidly 
upregulated while miR-155-5p is induced at a later stage (33, 
34). miR-155-3p acts at an early stage by targeting interleukin-1 
receptor-associated kinase 3 (IRAK3/IRAKM) mRNA which is 
a negative regulator of toll-like receptor signaling, facilitating 
TLR7-induced IFNα/β production, and the later induction of 
miR-155-5p (miR-155) terminates this production by targeting 
TGF-β activated kinase 1/MAP3K7 binding protein 2 (TAB 2) 
mRNA, a key signaling molecule of TLRs (33, 34). Thus, both 
strands of the miR-155 duplex are required for an efficiently 
co-ordinated pDCs response. Most studies have investigated the 
biology of the miR-155-5p strand and further studies are recom-
mended to investigate the evidence for a role of miR-155*(3p) in 
the regulation of the immune system and disease.
THe ReGULATiON OF miR-155 
eXPReSSiON
miR-155 expression is rapidly increased in response to infec-
tion or injury. Inducing factors include pathogen-associated 
molecular patterns and damage-associated molecular patterns 
(PAMPs/DAMPs (35)), alarmins (e.g., IL-1α) (36), and inflam-
matory stimuli, e.g., TNF, IL-1β, interferons (35), and hypoxia 
(37). In contrast, the expression of miR-155 is decreased by 
anti-inflammatory cytokines, resolvins, glucocorticoids, and 
posttranscriptional negative regulators, e.g., tristetraprolin; and 
this decreased expression of miR-155 is an important part of the 
negative-feedback mechanism terminating immune responses. 
For example, IL-10 decreases miR-155 expression by inhibiting the 
transcription factor Ets2. Thus, LPS-induced miR-155 expression 
is attenuated in Ets2-deficient mice (38). Regulatory cytokines, 
e.g., TGFβ can induce or inhibit miR-155 expression depending 
on the cell type and tissue environment (39–41). Resolvins are 
lipid mediators produced, e.g., by tissue macrophages, upon 
activation of Tyrosine-protein kinase Mer (MerTK) by apoptotic 
inflammatory cells (42) and have broad anti-inflammatory 
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effects. Resolvin D1 reduces inflammation in experimental 
corneal immunopathology by inhibiting miR-155 expression 
(43). Natural and synthetic glucocorticoids are highly effective at 
terminating acute inflammation, mediated in part by inhibition 
of miR-155 expression in a glucocorticoids receptor- and NF-κB-
dependent manner (44, 45). Inflammation can be controlled by 
the short half-life of mRNA of pro-inflammatory mediators (e.g., 
TNF, GM-CSF, IL-8, and CCL2). The rapid elimination of these 
mRNAs is mediated by miRNAs; or by specific proteins, e.g., 
tristetraprolin (TTP/ZFP36) that recognizes adenine–uridine 
rich elements (AREs) in mRNA and orchestrate its degradation. 
TTP inhibits miR-155, albeit by an unusual mechanism. Cells 
that overexpress TTP show high levels of miR-1 that putatively 
prevents the processing of miR-155 precursor to the mature 
form (46). In addition, the functions of mature miR-155 are 
counterbalanced by other miRs and the best example is miR-146. 
This, induced by the same stimuli as miR-155, targets TRAF6 and 
IRAK1 of the TLR/IL-1R signaling pathway and the timing of 
this provides feedback inhibition of the inflammatory response 
driven by miR-155 (47). This is evident in miR-146-deficient mice 
that develop inflammatory syndrome, autoimmunity, and cancer. 
miR-146-deficient cells show an increased expression of miR-155 
and their pro-inflammatory phenotype could be normalized by 
deletion of miR-155 (48), thus miR-155 and miR-146 can cross-
regulate inflammatory responses.
The miR-155 gene contains binding sites for multiple 
transcription factors including sites localized downstream and 
upstream of exon 1, e.g., 2 NF-κB binding sites (−1,697 and 
−1,150  bp from the transcription initiation site, respectively), 
SMAD4 (−600  bp), interferon-sensitive response element 
ISRE (−311  bp), interferon regulatory factors IRF (−200  bp), 
and AP-1 (−40 bp). There are also two Ets binding sites within 
the transcription start site, two Foxp3 binding sites in intron 
2, and three hypoxia-inducible factor-1 alpha binding sites in 
the promoter region (37, 49). This reflects the role of miR-155 
in co-ordination of the cell response to changes in the tissue 
environment (49).
THe FUNCTiONS OF miR-155 iN iNNATe 
iMMUNe CeLLS AND iTS DeReGULATiON 
iN RA
miR-155 Regulates Polarization of 
Macrophages
Macrophages can be polarized into different phenotypes in 
response to changes in tissue environments (50). For example, dur-
ing bacterial infection, TLRL- or T-helper 1 (Th1)/ILC1-derived 
IFNγ polarizes the pro-inflammatory macrophage phenotype 
that drives the protective immune response. However, if uncon-
trolled, this leads to chronic inflammation (50). Homeostasis can 
be restored by IL-10 and TGFβ derived from regulatory T-cells 
and by glucocorticoids, that induce macrophage phenotypes 
that mediate resolution of the immune response and facilitate 
tissue repair. IL-4/13 derived from Th2/ILC2 induces alternative 
macrophage phenotypes that are key in eliminating the parasites 
(51). However, they are also involved in mediating tissue repair 
by producing collagen components (proline), TGFβ, and CCL18. 
These changes in macrophage phenotypes are co-ordinated by 
miRNA networks, including miR-155 (52).
miR-155 is induced in monocyte/macrophages upon TLR/
IFNγ stimulation and drives their inflammatory response by epi-
genetic regulation of mRNA targets that are inhibitors of innate 
cell activation, e.g.,
 (i) phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 
(SHIP-1); an inhibitor of TLR/PI3/Akt kinase pathways.
 (ii) SOCS-1; a type 1 cytokine receptor/STAT pathway inhibitor.
 (iii) Bcl6, an inhibitor of NF-κB (53–56).
Bone marrow-derived murine macrophages deficient for 
miR-155 express decreased levels of pro-inflammatory cytokines 
following LPS stimulation (56, 57), as do miR-155-deficient 
murine RAW264.7 macrophages (58) and human macrophages 
gene-silenced for miR-155 (57); each associated with commen-
surate upregulation of SHIP-1.
In contrast to pro-inflammatory activation of macrophages, 
miR-155 inhibits the polarization of anti-inflammatory and 
repair macrophage phenotypes. miR-155 targets translation of 
multiple molecules in the IL-13/IL-4 pathway, including IL-13Rα, 
CEBP/β (59), and Mafb (60) and thus prevents development of 
the STAT6-driven anti-inflammatory and helminth-expulsive 
macrophage phenotype (61). Furthermore, miR-155 regulates the 
TGF-β signaling pathway, which is crucial for wound healing and 
homeostatic remodeling (62, 63). Louafi and colleagues found 
that miR-155 represses the TGFβ signaling molecule Smad2 in 
macrophages, preventing TGFβ-induced expression of IL-4Rα, 
amplification of TGFβ1/2 production, and the development of 
repair macrophages (63). We recently extended these findings by 
showing that miR-155 negatively regulates remodeling pathways 
in alveolar macrophages by targeting the transcription factor 
LXRα. miR-155-deficient mice had exacerbated bleomycin-
induced lung fibrosis compared to WT mice given bleomycin, 
and their alveolar macrophages showed an increased expression 
of Arginase 2, which is key for collagen production (36). Thus, 
miR-155 is a master-switch that determines the relative dynamics 
of TLR-induced inflammatory and IL-13/IL-4 or TGFβ-induced 
anti-inflammatory/repair phenotypes in macrophages (Figure 1). 
Inhibition of miR-155, e.g., by glucocorticoids or by regulatory 
T-cell-derived mediators (e.g., IL-10) allows the emergence of 
anti-inflammatory and tissue-repair macrophage phenotypes.
miR-155 Underlies the Activation of 
Monocytes and Macrophages in RA
Animal studies show that miR-155 drives experimental models 
of arthritis and its comorbidity, atherosclerosis (56, 57, 64). In 
RA patients, blood monocytes have significantly higher copy-
numbers of miR-155 than healthy controls, and the copy-number 
correlates strongly with disease activity score (DAS of 28 joints; 
DAS28) and with erythrocyte sedimentation rate; a non-specific 
biomarker of inflammation (65, 66). The expression levels of miR-
155 in patients in drug-induced remission and with low DAS 
were similar to levels in healthy donors, whereas levels in patients 
FiGURe 1 | miR-155 acts as a molecular rheostat to determine the duration of inflammation and the initiation of repair programs in macrophages. Depending on the 
expression levels of miR-155, macrophages can show opposite phenotypes. TLRLs induce high expression levels of miR-155. MiR-155 targets inhibitors of TLR/
cytokine receptor pathways and drive a pro-inflammatory phenotype as shown by the production of TNF, IL-1β, IL-6, and chemokines. In addition, high miR-155 
levels prevent a phenotypic switch to anti-inflammatory/repair macrophages by targeting (i) IL-13Rα, thus decreasing STAT6 activation and expression of STAT6-
dependent mediators, e.g., collagen production, inducing CCL18; (ii) TGFβ signaling molecule SMAD2, and the transcription factor LXRα, thus maintaining low levels 
of resolution/repair mediators, e.g., TGFβ, Arg2. Glucocorticoid and IL-10 override miR-155-induced phenotype by inhibiting its expression. The chronicity of 
synovial inflammation may be mediated by persistently high expression levels of miR-155 observed in synovial macrophages. Direct miR-155 targets are marked in 
bold font. TLR, toll-like receptors; IL-13Rα, interleukin-13 receptor alpha; TGFβ, transforming growth factor beta; SMAD2, small mothers against decapentaplegic 
homolog 2, LXRa, liver X receptor alpha; Arg2, arginase 2; GCS, glucocorticoids.
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with medium and high DAS were progressively increased. The 
expression of miR-155 in monocytes from patients with coronary 
heart disease is higher than normal and correlated with expres-
sion of TNF and IL-6 (67), suggesting that miR-155 expression in 
monocytes is closely associated with the degree of inflammatory 
activation (65).
Monocytes are recruited from the blood to the synovial fluid 
and to the synovial membrane where monocytes differentiate 
locally into pro-inflammatory macrophages (51, 68). This is an 
important step in RA progression and is mediated by locally pro-
duced chemokines (69). Both CD14+ monocytes from synovial 
fluid and CD68+ synovial tissue macrophages from RA patients 
with active disease have an activated phenotype (70–73) and 
produce pro-inflammatory cytokines, including TNF, IL-6, and 
GM-CSF that are targets for current successful RA therapies 
(74–76). Synovial fluid-derived monocytes can also differ-
entiate toward osteoclasts that mediate bone erosion (77, 78) 
and promote production of the osteoclastogenic and stromal 
cell-activating cytokine IL-17 by CD4+ T-cells which further 
contributes to bone and cartilage activation (70–72). We found 
that miR-155 is constitutively upregulated in both RA synovial 
tissue macrophages and synovial fluid monocytes compared 
to RA blood monocytes and non-inflammatory osteoarthritis 
controls (57). We demonstrated that the increased expression 
of miR-155 in synovial fluid CD14+ cells and synovial tissue 
macrophages was commensurate with reduced expression of 
SHIP-1, which thereby enabled their inflammatory phenotype, 
e.g., TNF production (57). In monocytes, miR-155 supports 
the expression of the integrin CD11a (LFA-1) that interacts 
with intercellular adhesion molecule-1 on endothelium and 
facilitates migration of monocytes into inflamed tissue (79). 
Moreover, monocyte miR-155 drives the production of inflam-
matory chemokines, including CCL3, CCL4, CCL5, and CCL8, 
and downregulates the expression of CCR2 (65). These find-
ings suggest that high levels of miR-155 in pro-inflammatory 
macrophages in synovial fluid and synovial tissue enables 
chemokine production and integrin expression that recruits 
precursors from the circulation, and then mediates the reten-
tion of these cells at sites of inflammation by downregulating 
chemokine receptor expression, and finally mediates local 
production of pro-inflammatory cytokines. Similarly, miR-155 
supports the development of advanced atherosclerotic lesions. 
In experimental models, miR-155, induced by inflammation 
and oxidized lipids, targets Bcl6 in lesional macrophages and 
FiGURe 2 | miR-155 regulates pro-inflammatory activation of monocytes/macrophages (pink) and dendritic cells (DCs) (blue). Inflammatory mediators that induce 
miR-155 expression in innate cells, include LPS, TNF, IFNβ, PAMPs, and DAMPs, while IL-10, GCS, and resolvins inhibit miR-155 expression. miR-155 promotes 
monocyte recruitment into inflamed tissue by the induction of appropriate chemokines, and then retains them by then downregulating CCR2 and inhibits their 
apoptosis by targeting APAF1 and CASP10. miR-155 drives inflammatory cytokine production by targeting SHIP-1, SOCS-1, and Bcl6. miR-155 represses the 
development of anti-inflammatory and repair macrophage phenotypes by targeting IL-13Rα, LXRα, and the TGFβ-signaling molecule SMAD2. In myeloid DCs, 
miR-155 targets PU.1 and decreases the endocytic function of DCs by downregulating DC-SIGN while supporting maturation of DCs and their T-cell stimulatory 
activity by targeting SOCS-1/SHIP-1 and c-fos. miR-155 limits plasmocytoid DC activation by decreasing type I IFN production by targeting TAB 2. Direct targets are 
marked in bold font. LPS, lipopolysaccharides; TNF, tumor necrosis factor; IFN, interferon; DAMPs, danger-associated molecular pattern; CCR2, C–C chemokine 
receptor type 2; PU.1: Spi-1 proto-oncogene; hematopoietic transcription factor PU.1; CCL, CC chemokine ligands; SHIP-1, phosphatidylinositol-3,4,5-trisphosphate 
5-phosphatase 1; SOCS-1, suppressor of cytokine signaling 1; TAB 2, TGF-beta activated kinase 1/MAP3K7 binding protein 2; APAF1, apoptotic peptidase 
activating factor 1; CASP10, caspase 10; TGF-β, transforming growth factor beta; IL, interleukin; DC-SIGN, DC-specific C-type lectin GCS, glucocorticoids.
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increases CCL2 production and recruitment of monocytes to 
vascular walls. Thus, miR-155 deficiency in macrophages ame-
liorated plaque formation (56).
Blood and synovial fluid monocytes from RA patients are 
resistant to spontaneous apoptosis and to apoptosis mediated by 
an agonistic anti-Fas antibody, as compared to blood monocytes 
of healthy donors (80–84). This resistance may contribute to the 
persistence of inflammatory monocytes and/or macrophages and 
their perpetuation of joint inflammation in RA. This resistance 
is due to the progressive inhibition of CASP10 and APAF1 by 
the increasing levels of miR-155 in RA cells. This was confirmed 
by miR-155 overexpression in healthy CD14+ cells that conferred 
resistance to spontaneous apoptosis (84). In vitro, mimicking the 
high expression levels of miR-155 in myeloid cells of patients with 
RA and cardiovascular disease by enforced expression of miR-
155 in healthy human monocytes/macrophages demonstrated 
that miR-155 triggers the spontaneous production of several 
pro-inflammatory cytokines, including TNF, IL-6, IL-1β, and 
IL-8, and decreases anti-inflammatory IL-10 production (57, 65, 
84). Thus, miR-155 overexpression promotes a pro-inflammatory 
phenotype in monocytes/macrophages, whereas in  vitro treat-
ment of RA patients’ synovial fluid CD14+ cells with miR-155 
antagonist de-repressed SHIP-1, inhibited the production of TNF 
(57) and restored cellular homeostasis.
Synovitis is driven by cross talk between synovial macrophages 
with fibroblasts (10) and emerging evidence suggests that miR-
NAs packaged into macrophage-derived exosomes regulate the 
function of adjacent cells, including fibroblasts. This has yet to 
be formally established is human synovial macrophages and 
fibroblasts; however, an elegant paper by Wang et al. showed that, 
upon cardiac injury, macrophages secrete miR-155-enriched 
exosomes that are absorbed by cardiac fibroblasts. miR-155 is 
released into the fibroblasts cytoplasm, inhibits SOCS-1, and 
enhances production of pro-inflammatory mediators, including 
IL-6. Administration of macrophage-derived exosomes contain-
ing miR-155 into miR-155-deficient mice exacerbates myocar-
dial infarction (85). Thus, it would be interesting to reveal the 
contribution of macrophage-derived miR-155 to the pathogenic 
phenotype of RA synovial fibroblasts.
In summary, sustained high levels of miR-155 in RA patients’ 
synovial monocytes and synovial tissue macrophages drive their 
pro-inflammatory activation and prevent the switch to anti-
inflammatory/repair phenotypes, thus preclude resolution of 
inflammation and initiation of repair (Figure 2).
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miR-155 Regulates Dendritic Cells’ (DCs) 
Maturation
Dendritic cells are key innate regulators of the adaptive 
immune response by activating antigen-specific T-cells. They 
have an important homeostatic function by either mount-
ing an immune response against pathogens or by inducing 
tolerance to self-antigens. To induce tolerance, DCs activate 
regulatory T-cells and/or induce anergy of antigen-specific 
effector T-cells; thereby terminating an immune response and 
preventing autoimmunity (86, 87). Mouse and human DCs 
consist of developmentally and functionally distinct DC subsets 
regulated by a network of cytokines and transcriptional factors 
(88). Upon stimulation with PAMPs/DAMPs DCs undergo 
a maturation process which is characterized by functional 
changes including decreased pathogen binding/endocytic 
activity, increased cytokine production and enhanced antigen 
presentation (89, 90). miRNA networks act at checkpoints 
during the development, differentiation and activation of DC 
subsets (88). miR-155 is dispensable for DC differentiation but 
is an important regulator of DC activation; mice deficient in 
miR-155 have normal numbers of CD8a+cDCs, CD8a−cDCs, 
and pDCs (91); however, miR-155 is readily induced in mouse 
and human DCs following TLR stimulation (35, 92, 93). TLR 
stimulation activates two cellular pathways resulting in DC 
maturation; MyD88-IRAK-TRAF6 and TRIF-IRF3-IFNα, and 
both are required for optimal NF-κB activation, expression of 
co-stimulatory molecules, and the production of cytokines, 
such as IL-1β or IL-12 (94, 95). miR-155 regulates the switch 
from the endocytic function to co-stimulatory/activatory func-
tion during DC maturation. miR-155 reduces the capacity of 
DCs to bind pathogens by downregulation of DC-SIGN via 
inhibition of transcription factor PU.1 (93), while enhancing 
cytokine production (91, 96, 97). Studies show that miR-155−/− 
DCs exhibit lower levels of MHC class II and co-stimulatory 
molecules (CD80, CD40), and a decrease in IL1β, TNF, IL12, 
and IL6 expression upon TLR-induced maturation compared 
to wild-type DCs, and they demonstrate a significantly lower 
ability to induce effector T-cells (91, 98). This may be mediated 
by miR-155 inhibition of c-fos, continued expression of which 
was shown to be detrimental for DC maturation (91). Similarly, 
inhibition of miR-155 in human monocyte-derived DCs caused 
a reduction in IL-12p70 production (97) whereas overexpres-
sion of miR-155 in mature DCs enhanced IL12p70 expression, 
leading to higher levels of IFN-γ being released by cocultured 
natural killer cells (97). It was proposed that miR-155 mediated 
these activatory functions of DCs through epigenetic regulation 
of SHIP-1 and SOCS-1 in a similar manner as in macrophages 
(96, 97).
Interestingly, miR-155 may terminate some DC functions by 
targeting TAB 2, a key adaptor molecule in the TLR/IL-1 pathway. 
These include termination of type I IFN or IL-1β production 
induced by TLR7- or LPS-mediated human monocyte-derived 
DC activation, respectively (55, 92). This discrepancy requires 
further investigation, but the nature of the stimulatory factor and 
the abundance of specific target at precise time–points during 
DC activation may determine whether miR-155 supports or 
terminates DC activation.
The Role of miR-155 in RA DC Activation
Rheumatoid arthritis peripheral blood, synovial fluid and synovial 
tissue DCs, in particular CD1c+ and monocyte-derived popula-
tions, show a constitutively activated phenotype by their increased 
expression of co-stimulatory molecules, cytokines (e.g., IL6) and 
their ability to activate autologous T-cells (99–102). It was shown 
recently that high levels of miRNA-34a that lead to repression 
of Axl, an inhibitor of DC activation, contribute to the activated 
phenotype of circulating and synovial CD1c+ in RA (100). The 
involvement of miR-155 to this phenotype is unknown. However, 
a role for DC miR-155 in driving experimental autoimmunity 
was shown by Lind et al. (96) in a model of diabetes in which 
self-antigen-pulsed, TLR-matured DCs lacking miR-155 have an 
impaired ability to break immune tolerance, while the transfer of 
self-antigen-pulsed DCs overexpressing miR-155 was sufficient 
to break tolerance even in the absence of TLR stimuli (96).
miR-155 FUNCTiONS iN ADAPTive 
iMMUNe CeLLS AND iS DeReGULATeD 
iN RA
Several lines of evidence support the role of miR-155 in T- and 
B-cell differentiation. miR-155 controls both effector and regula-
tory T-cell function (103) and regulates B-cell proliferation, 
germinal center formation, and antibody production (104). 
If aberrantly expressed, miR-155 contributes to initiation and 
progression of malignancies of B-cells and to autoimmunity.
miR-155 Controls B-Cell Proliferation
miR-155 is highly expressed in human B-cell lymphomas, 
especially in large B-cell lymphomas, Hodgkin lymphomas, 
and certain types of Burkitt lymphomas (104). Transgenic mice 
expressing miR-155 under the control of Eμ enhancer and VH 
promoter (Eμ-miR-155) develop aberrant accumulation of pre-
B-cells leading to the development of acute lymphoma. These 
cells have commensurately decreased expression of miR-155 
targets, e.g., SHIP-1 and CCAAT enhancer-binding protein beta 
(C/EBPbeta), which in B-cells have anti-inflammatory and anti-
proliferative functions (105, 106). miR-155 may promote survival 
and proliferation of naïve B cells in Eμ-miR-155 mice by targeting 
co-repressor partners Hdac4 (directly) and Bcl6 (indirectly), and 
their reduction leads to de-repression of Bcl6 targets, e.g., inhibi-
tor of differentiation-2, IL-6, cMyc, Cyclin D1, and Mip1α/ccl3; 
all of which promote cell survival and proliferation. Importantly, 
meta-analysis of microarray data from diffuse large B-cell 
lymphoma patients found that miR-155 expression correlated 
negatively with Bcl6 and Hdac4 expression, strongly supporting 
the role of the miR-155/Bcl6/Hdac4 pathway in the pathogenesis 
of human leukemias (107). miR-155 also regulates proliferation 
of mature B-cells in germinal centers by interfering with TGF-β 
signaling. TGF-β1 secreted in secondary lymphoid organs limits 
mature B-cell proliferation to maintain immune-system homeo-
stasis. miR-155 represses the TGF-β signaling molecule SMAD5, 
resulting in defective expression of the cell-cycle inhibitor p15/
p21 (108) and allowing B-cells unhindered progress through the 
cell-cycle.
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Systemic delivery of antisense miR-155, encapsulated in poly-
mer nanoparticles, inhibited miR-155 and slowed the growth of 
pre-B-cell tumors in vivo, confirming that miR-155 is an impor-
tant regulator of B-cell proliferation, and this may be a promising 
therapeutic option for lymphoma or leukemia (109).
miR-155 Controls Antibody Production  
by B-Cells
A critical stage of effector B-cell development is represented by 
germinal center (GC) formation. These structures develop when 
mature naïve B-cells encounter cognate antigen in the second-
ary lymphoid organs during which the B-cells undergo somatic 
hyper-mutation of their immunoglobulin variable region genes 
and class-switch recombination. Emerging B-cells that express 
high-affinity antibody further differentiate into plasma cells and 
memory B-cells (110). B-cells also contribute to the immune 
response by acting as antigen-presenting cells and fuel inflam-
mation by releasing a wide range of cytokine and chemokines 
(10). Thai and co-workers demonstrated that miR-155 plays an 
essential role in the regulation of GC formation. They found 
that miR-155-deficient mice had greatly reduced GC formation 
that was due to reduced production of TNF and LTα; obligate 
cytokines for GC neogenesis, by B-cells in response to antigen-
ligation of the B-cell receptor (103). In support of a pivotal role 
for miR-155 in B-cell activation, chronic lymphocytic leukemia 
(CCL) B-cells that expressed high miR-155, demonstrated miR-
155-dependent increased activation (calcium flux) induced 
by BCR ligation (111). The in vivo antibody response of miR-
155-deficient mice showed significantly reduced concentration 
of IgM and isotype-switched antigen-specific antibody class 
production (98, 112). Mechanistic studies by Vigorito et  al. 
(112) showed that miR-155 can directly target PU.1 mRNA 
via a predicted miR-155-binding site in the 3′ UTR, and that 
miR-155-deficient B-cells had increased PU.1 expression. 
Enforced expression of PU.1 in wild-type primary B-cells led 
to a reduction in the proportion of IgG1-expressing cells upon 
stimulation (112, 113). Mechanistically, miR-155 reduces PU.1 
expression that leads to the downregulation of Pax5, a PU.1-
dependent inhibitor of B-cell activation. This enables plasma cell 
differentiation along with the expression of other genes involved 
in B/T cellular interactions (e.g., Sema4a, Sema4b, Sema7a, and 
CD300If) facilitating antibody production (114).
miR-155 can also regulate the antigen-presenting function 
of B-cells. miR-155 targets the 3′UTR of CD1d in B-cells (115). 
Therefore, upregulation of miR-155 in B-cells, e.g., in chronic 
inflammation, can repress CD1d leading to impaired lipid-
antigen presentation by B-cells to invariant natural killer cells. 
This causes a breach of tolerance as shown by CD1d deficiency 
exacerbating lupus nephritis in the pristine-induced model (115).
Of additional relevance to autoimmune disease, miR-155 
modulates the B-cell response to immune complexes. The low-
affinity IgG inhibitory receptor FcγRIIB (Fcγ receptor IIB) is key 
in terminating proliferative signals delivered by autoantigen-
containing immune complexes by activating SHIP-1. Thai et al. 
showed that miR-155 can downregulate SHIP-1 and permit 
immune-complex-induced pathology in the Faslpr model of 
autoimmune lupus (113), and this may also be relevant to the 
signaling of the immune complexes in RA.
The Role of miR-155 in RA B-Cells
The onset of RA is preceded by preclinical immunological 
changes, e.g., the production of anti-citrullinated peptides 
antibodies (anti-CCP/ACPA) and rheumatoid factor, which 
reflect the loss of immunological tolerance to self-antigens 
(116), and this places B-cells at the center of RA pathogenesis. 
This is confirmed by the efficacy of B-cell depletion therapy in 
RA patients (117). The proportion of B-cell subsets is altered 
in the blood of RA patients (118, 119) with higher percentages 
and absolute numbers of naïve B-cells at the onset of disease, 
and increased proportions of double-negative (IgD−/CD27−) 
memory B-cells and plasmablasts in patients with established 
RA (120).
As previously stated, miR-155 was first described as an 
important epigenetic regulator of antibody synthesis (98, 112). In 
experimental models of arthritis, the production of anti-collagen 
antibodies was significantly decreased in miR-155-deficient mice 
compared to wild type (57, 64), and these mice did not develop 
arthritis. In RA patients, we found that the expression of miR-155 
in B-cells is increased and is maximal during the early phase of 
disease. This increase is predominant in double-negative (IgD−/
CD27−) memory B-cells (121), and occurs in ACPA+ but not 
ACPA− RA patients suggesting a role in autoantibody produc-
tion. The IgD−/CD27− B-cell population is increased in other 
autoimmune diseases, including SLE (122, 123) and is important 
for IgG+ plasmablast generation (124). In a study of paired 
peripheral blood–synovial fluid samples from RA patients, 
miR-155 expression was higher in B-cells from the synovium 
compared with B-cells from blood. Mediators, including IL-6, 
BAFF, IgM, CD40L, and IL-21 were increased in synovial fluid, 
and these were able to upregulate miR-155 expression in B cells 
in  vitro. In addition, in  situ hybridization revealed that most 
of the resident synovial tissue CD20+ cells in germinal-center-
like follicles were miR-155 positive. Commensurate with the 
increased miR-155 expression, synovial fluid-derived B-cells of 
RA patients showed reduced expression of the miR-155 target 
PU.1 in ACPA+ compared to ACPA− patients, and a reduced 
proportion of PU.1+ cells among the resident CD20+ cells in 
synovial follicles (121). Inhibition of endogenous miR-155 in RA 
B-cells led to the restoration of PU.1 expression and inhibition of 
antibody production (121) suggesting a key role of miR-155 in 
autoantibody production by B-cells in RA. Commensurate with 
this, the expression of miR-155 in circulating B-cells of ACPA+ 
RA is significantly higher than that of similarly inflamed patients 
with psoriatic arthritis (PsA), in which B-cells are minimally 
involved in pathogenesis (121). In addition, the expression of 
miR-155 in circulating B-cells is particularly high in RA patients 
with follicular synovitis; which is a prognostic factor for poor 
treatment response (125). Thus, miR-155 expression in RA 
circulating B-cells can serve as a biomarker of B cell activation 
and lymphoid/follicular synovitis among the three RA synovial 
pathotypes identified (myeloid, lymphoid/follicular, and fibroid) 
(126). A summary of miR-155 function in B-cells is presented 
on Figure 3.
FiGURe 3 | miR-155 supports B-cell proliferation and antibody production. Several cytokines and TLR-ligands can induce miR-155 expression in B-cells. These 
include LPS, IL-6, IL-21, CD40L, IFN-α, and BAFF, while TGFβ inhibits miR-155 expression. By targeting SHIP-1, C/EBPβ, the Hdac4/Bcl6 complex, and the TGFβ 
signaling molecule SMAD5, miR-155 drives proliferation and resistance to apoptosis of B-cells. miR-155, by epigenetic regulation of PU.1, is indispensable for B-cell 
maturation, migration, interaction with T-cells, and antibody production. Moreover, miR-155 regulates the surface expression of CD1d on B-cells, influencing the 
cellular cross talk with invariant NK T-cells. Direct targets are marked in bold font. LPS, lipopolysaccharides; IL, interleukin; TLR, toll-like receptor; Bcl, B-cell 
lymphoma; SMAD5, small mother against decapentaplegic 5; CD, cluster designation; PU.1, Spi-1 Proto-Oncogene; Sema, semaforin; NK, natural killer; BAFF, 
B-cell activating factor; CD40L, CD40 ligand. TGF-β, transforming growth factor beta; SHIP-1, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; Bcl6, 
B-cell lymphoma; HDAC4; histone deacetylase 4; C/EBPβ: CCAAT/enhancer-binding protein beta; NFAM1, NFAT activating protein with ITAM motif 1; CXCR4; 
C–X–C chemokine receptor type 4; CCR7, C–C chemokine receptor type 7; S1Pr1, sphingosine-1-phosphate receptor 1; TNFsF4, tumor necrosis factor (ligand) 
superfamily, member 4; CD300lf, CMRF35-like molecule 1.
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miR-155 is a Regulator of T-Cell 
Differentiation
In response to appropriate stimuli, CD4+ T-cells can differentiate 
into different phenotypes that include the Th1, Th2, Th17, fol-
licular helper T (Tfh) cells, and T-regulatory (Treg) cell lineages 
with distinct functions (127). This differentiation is influenced 
by cytokines and by the expression and activation of phenotype-
specific transcription factors (128). miRNAs have been implicated 
in CD4+ T-cell differentiation (129, 130) and miR-155 is central 
to this process (98, 131).
T-Helper 1
Rodriguez and colleagues examined the T-cell response of miR-
155-deficient mice immunized with T-dependent antigen (tetanus 
toxin fragment C) and showed that splenocytes produced sig-
nificantly reduced concentrations of IL-2 and IFN-γ compared to 
wild-type mice (98). An intrinsic requirement for miR-155 to Th1 
development was confirmed in vitro by comparing the cytokine 
production by WT and miR-155−/− CD4+ cells in culture follow-
ing anti-CD3 and anti-CD28 stimulation, which demonstrated 
reduced IFNγ production by miR-155−/− cells (98). In keeping 
with these observations, Banerjee and co-workers showed that 
overexpression of miR-155 in activated CD4+ T-cells promoted 
Th1 differentiation by targeting IFN-γRα thereby decreasing the 
sensitivity of Th1 cells to the anti-proliferative effects of IFN-γ 
(131).
Th2
miR-155 was initially described as a negative regulator of Th2 
commitment through the repression of its target c-Maf, which 
is an IL-4 promoter transactivator (98). CD4+ T-cells from 
miR-155-deficient mice exhibit preferential Th2 differentiation 
upon activation (132–134). miR-155-deficient mice have an age-
dependent increased number of Th2 cells and develop spontane-
ous airway remodeling due to the action of Th2 cytokines (98). 
In keeping with this, we recently reported that miR-155-deficient 
mice are susceptible to exacerbated bleomycin-induced lung 
fibrosis (36). In contrast, Malmhall et  al., using an antigen-
induced asthma model, observed that miR-155-deficient mice 
had decreased activation of Th2 cells and decreased production 
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of IL-4, IL-5, and IL-13, decrease lung eosinophilia and fewer 
physiological changes compared with wild-type mice (135). 
The potential inhibition of Th2 development was not associated 
with c-Maf changes but with depression of PU.1 that negatively 
regulates the expression of GATA3, the key transcription factor 
for Th2 cell function. Similarly, Okoye et al. described a Th2-cell-
selective role for miR-155 in the development of an allergic airway 
model. They demonstrated that miR-155 inhibits the expression 
of sphingosine-1-phosphate receptor 1, which is required for 
lymphocyte egress from lymphoid organs, thus mice with miR-
155−/− T-cells had reduced airway pathology (136). This suggests 
that the miR-155 may highlight different roles for Th2 responses 
in acute allergic inflammation compared with fibrosis. It is pos-
sible that resident tissue memory T-cells are more involved in 
age-related and bleomycin-induced chronic lung remodeling, 
whereas recently activated recruited T-cells are more involved in 
acute airway inflammation.
Th17
Th17 lymphocytes have higher expression levels of miR-155 
compared with other T-cell subset lineages (137). miR-155 is 
upregulated in Th17 cells by STAT3, IRF-4 and RORγt and sup-
ports the development of Th17 by inhibiting its epigenetic target 
Jarid2, which itself is an epigenetic suppressor of Il22, Il10, Il9, 
and Atf3 (137), and by suppressing SOCS-1, thereby facilitating 
IL-6/STAT3 signaling (138). Accordingly, miR-155-deficient 
mice have substantially reduced numbers of Th17 cells as dem-
onstrated by reduced expression of IL-17A (139), IL-22, IL-6, and 
IL-23R (64, 139–141).
Follicular T-Helper Cells (Tfh)
Follicular T-helper cells cells are key in GC formation and 
antibody production by providing help to B-cells in secondary 
lymphoid tissue. Elegant work led by Tang showed that miR-155 
is indispensable in the development of Tfh. Using CD4+-specific 
miR-155-deficient mice, the authors showed reduced levels of 
Tfh (CXCR5+PD1+ Bcl6+) and consequently less-developed GCs 
and reduced antigen-specific antibody production in a variety 
of immunization schedules. Silencing of two proteins, Fosl2 (a 
component of AP1) and to a lesser extent Peli1 (E3 ubiquitin 
ligase) in miR-155−/− CD4+ T-cells, resulted in improved devel-
opment of Tfh cells following immunization, suggesting that 
miR-155 mediates Tfh differentiation by downregulating these 
two targets (142).
Regulatory T-Cells
There is abundant evidence that miR-155 can promote the 
development of Tregs. These cells are important to maintain 
immunological tolerance by limiting pathogenic Th-cell 
responses. Tregs are dependent on IL-2/STAT5 signaling and 
are characterized by the expression of Foxp3. This transcription 
factor induces miR-155 which then upregulates STAT5 phos-
phorylation by its epigenetic blockade of SOCS-1-mediated 
inhibition of STAT5. miR-155-deficient mice have reduced 
numbers of Tregs in the thymus and in peripheral blood due 
to attenuated IL-2 signaling by de-repressed SOCS-1 (143, 
144). Cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is 
an effector molecule of Tregs that binds to CD28 and limits 
the activation of effector T-cells, is a putative mRNA target of 
miR-155 (143, 145). However, Tregs from miR-155-deficient 
mice express normal levels of CTLA-4 suggesting that it is not 
under the epigenetic control of miR-155, at least in Tregs in 
mice. In contrast, Sonkoly et al. showed that miR-155 targets 
CTLA-4 mRNA in human effector T-cells. This group observed 
an increased level of miR-155 and decreased level of CTLA-4 
in effector T-cells of patients with atopic dermatitis, suggesting 
that miR-155 inhibition of CTLA-4 contribute to activation 
of effector T-cells in the skin (146). Thus, miR-155/CTLA-4 
interactions might be cell-type and species-specific.
CD8+
Deletion of Dicer in cytotoxic CD8+ T-cells causes an impaired 
immune response to pathogens (147). Gracias et al. (148) found 
miR-155 upregulated in primary effector and effector memory 
CD8+ T-cells as compared to naive and central memory CD8+ 
cells. Antiviral CD8+ T-cell responses and viral clearance were 
impaired in miR-155-deficient mice, while miR-155 overex-
pression augmented antiviral CD8+ T-cell responses in  vivo. 
Increased miR-155 inhibited the type I interferon response in 
CD8+ cells while miR-155-deficient CD8+ T-cells had enhanced 
type I interferon signaling and were more susceptible to IFNs 
antiproliferative effect. Inhibition of type I interferon-associated 
transcription factors STAT1 or IRF7 resulted in enhanced 
responses of miR-155-deficient CD8+ T-cells to viral infection 
in  vivo (148). This suggests that miR-155 maintains prolifera-
tion of CD8+ in response to viral antigen by downregulation of 
STAT1/IRF7.
The Role of miR-155 in T Cells in RA
In experimental arthritis, miR-155-deficiency affects Th17  cell 
polarization. Production of IL-17 and IL-22 are significantly 
reduced in miR-155-deficient mice compared to wild type (64). 
Smigielska-Czepiel and colleagues provided important insight 
into the differential expression of specific miRNAs in human T-cell 
subsets, especially naive and memory T-cells in peripheral blood 
and synovial fluid in RA patients (149). Synovial fluid T-cells are 
predominantly memory T-cells (150) and are characterized by 
high expression of miR-155 compared with naive T-cells (149), 
thus miR-155 in this compartment may support local production 
of IL-17 and IFNγ by autoreactive T-cells.
Despite the presence of many Tregs in the synovial fluid of RA 
(151–153), joint inflammation persists in most patients regard-
less of the treatment regimen. One interpretation is that there is a 
functional defect in these Tregs, e.g., due to inhibition of Foxp3 by 
TNF (154) that is in high concentration in synovial fluid; or that 
the effector T-cells are resistant to the regulatory action of Tregs 
(155). Blood Tregs from RA patients have significantly lower 
expression of miR-155 than healthy controls (156). However, 
correcting this expression by enforcing exogenous miR-155 in 
RA Tregs in vitro enhanced their production of TNF, IL-17, and 
IFNγ after 24  h upon stimulation with anti-CD3/CD28 (156). 
This suggests that altering the expression of miR-155 alone is not 
sufficient to restore the immunosuppressive function of RA Tregs 
but promotes pathogenic cytokine production instead.
FiGURe 4 | miR-155 drives differentiation of T-helper 1 (Th1), Th17, Tfh and is indispensable for the function of Tregs. miR-155 has multiple effects on T-cell 
function. miR-155 promotes: Th1 by targeting IFNRα; Th17 by targeting Jarid2 and SOCS-1; and follicular helper T-cells (Tfh) by targeting Fosl2 and Peli. Mir-155 
supports the function of regulatory T-cells (Treg) by targeting SOCS-1 that enables IL-2 signaling. miR-155 regulates Th2 development and function; e.g., inhibiting 
development by targeting c-maf; a key transcription factor for IL-4 and regulating an egress of T cells from the lymph nodes by targeting S1PR1. Direct targets are 
marked in bold font. TGF, transforming growth factor; IL, interleukin; TCR, T cell receptor; IFN, interferon; SOCS-1, suppressor of cytokine signaling 1; STAT, signal 
transducer and activator of transcription; SHIP, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; c-maf, transcription factor Maf; reg, regulatory; JARID2, 
Jumonji, AT rich interactive domain 2; SP1R1, sphingosine-1-phosphate receptor-1.
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In summary, miR-155 is indispensable for activation of Th1, 
Th17, Tfh, CD8+, and Treg while inhibiting Th2 (Figure  4). 
Sustained high expression of miR-155 in synovial effector T-cells 
may contribute to chronic production of IFNγ, IL-17 and facili-
tate differentiation of T-cells toward Tfh cells in RA.
iS THeRe THeRAPeUTiC POTeNTiAL iN 
TARGeTiNG miR-155 iN ARTHRiTiS?
The literature and our own experimental findings summarized 
in this review indicate that miR-155 is a key mediator of chronic 
activation of innate and adaptive immunity in RA. Its contribution 
to RA pathogenesis might be more profound than in other forms 
of inflammatory arthritis such as PsA due to the involvement of 
miR-155 in driving autoantibody production in RA. A cross-
sectional analysis of RA patients with different clinical responses 
to treatments revealed that miR-155 expression becomes reduced 
in the monocytes of RA patients who responded well to conven-
tional disease-modifying anti-rheumatic drugs (e.g., methotrex-
ate) or to biological DMARDs (65). Consistent with this, there are 
prospective studies in psoriasis patients showing that the expres-
sion levels of miR-155 in PBMCs decreased upon successful 
treatment with methotrexate as compared to pre-treatment 
levels (157). These observations suggest that a reduction of high 
to normal expression of miR-155 reflects a good clinical response 
to therapies that reduce inflammation (Figure 5). However, the 
effects of current anti-inflammatory (e.g., anti TNF, anti-IL-6R) 
or anti-adaptive immunity (e.g., CTLA-4) therapies on miR-155 
expression in B-cells and Th17 cells still needs to be investigated 
in prospective studies.
Chronic inflammation and continuous activation of adaptive 
immunity generate pro-inflammatory cytokines and autoanti-
bodies that fuel high levels of miR-155 expression thus locking 
the immune system into an activatory state. Targeting miRNAs 
has proven to be a useful therapeutic option in infectious diseases, 
cancer and recently in tendinopathy (8, 9). The most clinically 
advanced example of targeting miRNA is neutralization of miR-
122 to treat hepatitis C infections (HCV) that is currently in phase 
IIa clinical trials. miR-122 supports the replication of HCV (158) 
and treatment with antimiR-122 (Mirvirasen; Roche/Santaris 
and Regulus Therapeutics) achieved a reduction in viral titers in 
HCV-infected patients (8). Another miR-targeted therapeutic that 
reached clinical development is a mimic of the tumor suppressor 
miR-34. miR-34a targets pro-apoptotic proteins and cell-cycle 
inhibitors, and is downregulated in many human cancers (159). 
FiGURe 5 | Regulation of miR-155 expression in RA. Initiators of inflammation,e.g., PAMPs and DAMPs increase miR-155 expression. Homeostatic resolution is 
controlled by anti-inflammatory mediators that act in part by decreasing miR-155 expression (e.g., IL-10, GCS, TTP, resolvins) or counterbalancing its function, e.g., 
miR-146. In rheumatoid arthritis (RA), there is persistent inflammation and activation of adaptive immunity which maintain high expression levels of miR-155 that lock 
the immune system in an activatory state. A successful response to treatment (reduced systemic and synovial inflammation) in RA patients is associated with a 
reduction of miR-155 expression (at least in monocytes). PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; GCS, 
glucocorticoids; TTP, tristetraproline; cDMARD, conventional disease-modifying anti-rheumatic drugs; TNFi, TNF inhibitors.
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The miR-34 mimic MRX34 (Mirna Therapeutics), encapsulated 
in lipid nanoparticles, is currently being tested in several solid 
and hematological malignancies (8). We showed recently that 
chronic tendinopathy is driven by deregulation of the IL-33/
miR-29 pathway leading to the production of pro-inflammatory 
mediators and collagen 3 with weak tensile strength, thus limiting 
effective tendon healing (160). The results from a randomized, 
blinded trial of local tendon miR-29a replacement therapy in an 
equine model, that closely mimics human disease, changed the 
collagen composition toward stronger collagen 1 and improved 
early tendon healing (9). Human trials will be conducted in the 
near future.
To date, the potential clinical outcome of miR-155 inhibition 
in arthritis is based on findings from animal models, and from 
ex vivo studies using RA patient-derived cells. miR-155-deficient 
mice are resistant to arthritis, and inhibition of miR-155 using 
specific antimiR in a collagen-induced arthritis model reduced 
the clinical onset and severity of disease (161). Thus, inhibit-
ing miR-155 may represent an attractive therapeutic option. 
However, systemic inhibition of miR-155 may compromise 
its other physiological functions and lead to unwanted conse-
quences. Experimental and clinical evidence suggest that miR-
155 is indispensable for normal immunity against pathogens 
(55, 103). In addition, miR-155 in liver macrophages (Kupffer 
cells) is key in the regulation of lipid metabolism. Mir-155 
regulates the expression levels of a target mRNA LXRα which 
is a transcription factor that controls lipid metabolism and lipid 
efflux, thus miR-155-deficient mice have an increased level of 
circulating cholesterol and develop fatty liver (liver steatosis) 
while on a high-fat diet (162). Furthermore, miR-155 controls 
lung interstitial remodeling by regulating the proliferation and 
collagen production of lung fibroblasts, the repair macrophage 
phenotype, and the production of type 2 cytokines (36, 98). miR-
155-deficient mice develop spontaneous age-related lung fibro-
sis and exacerbated lung fibrosis associated with administration 
of bleomycin. The lack of miR-155 epigenetic control in these 
murine lung fibroblasts resembles the deregulated in  vitro 
pro-fibrotic behavior of lung fibroblasts from patients with 
idiopathic pulmonary fibrosis (36, 98). This suggests that a 
therapeutic strategy in arthritis of systemic targeting of miR-
155, or pan-macrophage-specific delivery of miR-155 inhibitors 
via liposomes might have detrimental effects. There may be an 
alternative method of delivery of a miR-155-inhibitor. An elegant 
study led by Cheng et  al. (163) showed that delivery of anti-
miR-155 could be specifically targeted to hypoxic tissues such as 
tumors or inflamed tissues with an ambient low pH created by 
anaerobic metabolism. The authors linked antimiR-155 with a 
low pH-induced transmembrane structure (pHLIP). At pH less 
than 7, the C-terminus of pHLIP inserts across lipid bilayers and 
facilitates delivery of the attached antimiR-155. Inside the cell, 
the disulfide bond between pHLIP and antimiR-155 is reduced 
in the cytosol and the intracellular antimiR-155 is free to inhibit 
miR-155. The inflamed synovial tissue environment is hypoxic 
(164), thus this novel delivery systems could inhibit miR-155 
in arthritis and avoid off-target side effects such as reduced 
protective immunity, fibrosis, or liver steatosis. Alternatively, 
enhancing activation of inhibitors of cell activation that are 
repressed by miR-155, e.g., SHIP-1 by specific activators might 
be a safer option (165). SHIP-1 activator (AQX-1125) has gen-
erated positive clinical data from clinical trials in COPD and 
allergic asthma, demonstrating a favorable safety profile and 
anti-inflammatory activity (trial number: NCT01954628).
FUTURe DiReCTiONS
There are gaps in the identification and characterization of all 
direct miR-155 targets and the physiological impact of miR-155 
inhibition on these targets would need to be revealed before 
anti-miR-155 therapy can be considered. Moreover, understand-
ing the role of miR-155 that is naturally contained in vesicles 
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transferred between cells in the synovium may provide insight 
into mechanisms of chronicity. Investigation of miR-155 in DCs 
and B-cells in the preclinical phase of RA (asymptomatic ACPA 
positive individuals) would help to dissect its role in the regula-
tion of the breach of immunological tolerance. A biomarker for 
treatment responses in arthritis would be of considerable clinical 
value, therefore, prospective studies using cohorts of RA patients 
at different stages of disease would validate whether miR-155 
could fulfill this additional role.
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